Miriam Redrado

1.8k total citations
39 papers, 1.1k citations indexed

About

Miriam Redrado is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Miriam Redrado has authored 39 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 19 papers in Oncology and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Miriam Redrado's work include Cancer Cells and Metastasis (9 papers), Lung Cancer Treatments and Mutations (8 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Miriam Redrado is often cited by papers focused on Cancer Cells and Metastasis (9 papers), Lung Cancer Treatments and Mutations (8 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Miriam Redrado collaborates with scholars based in Spain, United States and Germany. Miriam Redrado's co-authors include Alfonso Calvo, Leyre Larzábal, Paul Nguewa, Luis M. Montuenga, María Villalba, Irene Manrique, Alice Agliano, Diego Serrano, Anne‐Marie Bleau and Francisco Expósito and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Miriam Redrado

38 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Miriam Redrado Spain 20 544 518 270 233 177 39 1.1k
Julia V. Burnier Canada 21 592 1.1× 408 0.8× 318 1.2× 174 0.7× 123 0.7× 73 1.2k
Michela Croce Italy 21 436 0.8× 490 0.9× 184 0.7× 510 2.2× 124 0.7× 47 1.2k
Alejandro Parrales United States 13 698 1.3× 463 0.9× 348 1.3× 173 0.7× 110 0.6× 19 1.1k
Rajkumar Ganesan United States 22 618 1.1× 321 0.6× 131 0.5× 400 1.7× 81 0.5× 37 1.3k
Caterina Ieranò Italy 20 546 1.0× 917 1.8× 155 0.6× 462 2.0× 119 0.7× 34 1.4k
Eleonora Rofi Italy 20 621 1.1× 563 1.1× 583 2.2× 116 0.5× 631 3.6× 39 1.4k
Florian Castet Spain 8 437 0.8× 524 1.0× 334 1.2× 310 1.3× 379 2.1× 20 1.4k
D A Kirschmann United States 11 634 1.2× 220 0.4× 217 0.8× 166 0.7× 143 0.8× 15 1.0k
A. Coates United States 11 678 1.2× 802 1.5× 123 0.5× 246 1.1× 245 1.4× 19 1.3k
Nino Keshelava United States 19 914 1.7× 454 0.9× 293 1.1× 134 0.6× 120 0.7× 33 1.4k

Countries citing papers authored by Miriam Redrado

Since Specialization
Citations

This map shows the geographic impact of Miriam Redrado's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miriam Redrado with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miriam Redrado more than expected).

Fields of papers citing papers by Miriam Redrado

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miriam Redrado. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miriam Redrado. The network helps show where Miriam Redrado may publish in the future.

Co-authorship network of co-authors of Miriam Redrado

This figure shows the co-authorship network connecting the top 25 collaborators of Miriam Redrado. A scholar is included among the top collaborators of Miriam Redrado based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miriam Redrado. Miriam Redrado is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Larrinaga, Gorka, Miriam Redrado, Ana Loizaga‐Iriarte, et al.. (2025). Spatial expression of fibroblast activation protein-α in clear cell renal cell carcinomas revealed by multiplex immunoprofiling analysis of the tumor microenvironment. Cancer Immunology Immunotherapy. 74(2). 53–53. 4 indexed citations
2.
Redrado, Miriam, Larissa S. Carnevalli, Simon T. Barry, et al.. (2024). Abstract LB115: Strong antitumor effect elicited by inhibition of AKT or FOXP3 in combination with anti-PD-L1 in Pten mutant lung squamous cell carcinoma. Cancer Research. 84(7_Supplement). LB115–LB115.
3.
Anfray, Clément, Francesco Mainini, Elisabeth Digifico, et al.. (2021). Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity. Journal for ImmunoTherapy of Cancer. 9(9). e002408–e002408. 67 indexed citations
4.
Piulats, Josep M., Enrique Espinosa, Luis de la Cruz‐Merino, et al.. (2021). Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). Journal of Clinical Oncology. 39(6). 586–598. 145 indexed citations
5.
Esteban, Emilio, Francisco Expósito, Guillermo Crespo, et al.. (2021). Circulating Levels of the Interferon-γ-Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic Therapy. Cancers. 13(11). 2849–2849. 13 indexed citations
6.
Expósito, Francisco, María Villalba, Miriam Redrado, et al.. (2019). Targeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery. Cancer Letters. 453. 21–33. 27 indexed citations
7.
Redín, Esther, María Villalba, Francisco Expósito, et al.. (2019). P2.03-38 Identification of a Novel Synthetic Lethal Vulnerability in Non-Small Cell Lung Cancer by Co-Targeting TMPRSS4 and DDR1. Journal of Thoracic Oncology. 14(10). S698–S699. 1 indexed citations
8.
9.
Villalba, María, Francisco Expósito, María J. Pajares, et al.. (2019). TMPRSS4: A Novel Tumor Prognostic Indicator for the Stratification of Stage IA Tumors and a Liquid Biopsy Biomarker for NSCLC Patients. Journal of Clinical Medicine. 8(12). 2134–2134. 18 indexed citations
10.
Expósito, Francisco, María Villalba, María J. Pajares, et al.. (2018). P1.03-24 TMPRSS4: A Novel Prognostic Biomarker and Therapeutic Target in NSCLC. Journal of Thoracic Oncology. 13(10). S521–S521. 2 indexed citations
11.
Jiménez‐Fonseca, Paula, M Navarro, Alberto Carmona‐Bayonas, et al.. (2018). Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib. Oncotarget. 9(97). 36894–36905. 11 indexed citations
12.
Bleau, Anne‐Marie, Miriam Redrado, Estanislao Nistal‐Villán, et al.. (2017). miR-146a targets c-met and abolishes colorectal cancer liver metastasis. Cancer Letters. 414. 257–267. 45 indexed citations
13.
Villalba, María, Ángel Díaz‐Lagares, Miriam Redrado, et al.. (2016). TMPRSS4 protein overexpression and its promoter hypomethylation predict poor prognosis in squamous lung cancer patients. European Journal of Cancer. 61. S14–S14. 1 indexed citations
14.
Nguewa, Paul, Irene Manrique, Miriam Redrado, et al.. (2014). Id-1B, an Alternatively Spliced Isoform of the Inhibitor of Differentiation-1, Impairs Cancer Cell Malignancy Through Inhibition of Proliferation and Angiogenesis. Current Molecular Medicine. 14(1). 151–162. 9 indexed citations
15.
Larzábal, Leyre, et al.. (2014). TMPRSS4 regulates levels of integrin α5 in NSCLC through miR-205 activity to promote metastasis. British Journal of Cancer. 110(3). 764–774. 49 indexed citations
16.
17.
Ibáñez, Elena, Alice Agliano, Celia Prior, et al.. (2012). The Quinoline Imidoselenocarbamate EI201 Blocks the AKT/mTOR Pathway and Targets Cancer Stem Cells Leading to a Strong Antitumor Activity. Current Medicinal Chemistry. 19(18). 3031–3043. 36 indexed citations
18.
Ponz‐Sarvisé, Mariano, Paul Nguewa, Jackeline Agorreta, et al.. (2011). Inhibitor of Differentiation-1 as a Novel Prognostic Factor in NSCLC Patients with Adenocarcinoma Histology and Its Potential Contribution to Therapy Resistance. Clinical Cancer Research. 17(12). 4155–4166. 40 indexed citations
19.
Agliano, Alice, Inés Martín-Padura, Paola Marighetti, et al.. (2011). Therapeutic Effect of Lenalidomide in a Novel Xenograft Mouse Model of Human Blastic NK Cell Lymphoma/Blastic Plasmacytoid Dendritic Cell Neoplasm. Clinical Cancer Research. 17(19). 6163–6173. 32 indexed citations
20.
Nguewa, Paul, Juan A. Díaz-González, Ernest Hamel, et al.. (2009). The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer. British Journal of Cancer. 100(6). 932–940. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julia V. Burnier Breakdown of academic impact, for papers by Michela Croce Breakdown of academic impact, for papers by Alejandro Parrales Breakdown of academic impact, for papers by Rajkumar Ganesan Breakdown of academic impact, for papers by Caterina Ieranò Breakdown of academic impact, for papers by Eleonora Rofi Breakdown of academic impact, for papers by Florian Castet Breakdown of academic impact, for papers by D A Kirschmann Breakdown of academic impact, for papers by A. Coates Breakdown of academic impact, for papers by Nino Keshelava
Rankless by CCL
2026